Ocugen (OCGN) said Thursday that the first patient has been dosed in the phase 1 clinical trial of OCU200 for diabetic macular edema.

The trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal injection in three cohorts, the biotechnology company said.

Ocugen said it plans to seek approval for OCU200 as a first-line therapy for diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration.

Price: 0.72, Change: -0.01, Percent Change: -0.86